Alto Neuroscience, Inc.

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, VRTX has a market cap of 112.2B. Regarding current trading prices, ANRO is priced at $25.47, while VRTX trades at $441.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas VRTX's P/E ratio is 28.85. In terms of profitability, ANRO's ROE is -0.48%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, ANRO is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check VRTX's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, REGN has a market cap of 78.3B. Regarding current trading prices, ANRO is priced at $25.47, while REGN trades at $753.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas REGN's P/E ratio is 18.17. In terms of profitability, ANRO's ROE is -0.48%, compared to REGN's ROE of +0.15%. Regarding short-term risk, ANRO is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check REGN's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ANRO is priced at $25.47, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ANRO's ROE is -0.48%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, ANRO is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check VRNA's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, ARGX has a market cap of 52.1B. Regarding current trading prices, ANRO is priced at $25.47, while ARGX trades at $840.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas ARGX's P/E ratio is 42.92. In terms of profitability, ANRO's ROE is -0.48%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, ANRO is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check ARGX's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, ALNY has a market cap of 44.2B. Regarding current trading prices, ANRO is priced at $25.47, while ALNY trades at $333.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas ALNY's P/E ratio is 141.82. In terms of profitability, ANRO's ROE is -0.48%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, ANRO is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check ALNY's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ANRO is priced at $25.47, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ANRO's ROE is -0.48%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ANRO is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check SGEN's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, INSM has a market cap of 31.6B. Regarding current trading prices, ANRO is priced at $25.47, while INSM trades at $146.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas INSM's P/E ratio is -22.86. In terms of profitability, ANRO's ROE is -0.48%, compared to INSM's ROE of -1.68%. Regarding short-term risk, ANRO is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for ANRO.Check INSM's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, RVMD has a market cap of 30.2B. Regarding current trading prices, ANRO is priced at $25.47, while RVMD trades at $152.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas RVMD's P/E ratio is -25.64. In terms of profitability, ANRO's ROE is -0.48%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, ANRO is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for ANRO.Check RVMD's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, UTHR has a market cap of 25.3B. Regarding current trading prices, ANRO is priced at $25.47, while UTHR trades at $577.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas UTHR's P/E ratio is 20.75. In terms of profitability, ANRO's ROE is -0.48%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ANRO is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check UTHR's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, BNTX has a market cap of 25B. Regarding current trading prices, ANRO is priced at $25.47, while BNTX trades at $99.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas BNTX's P/E ratio is -18.15. In terms of profitability, ANRO's ROE is -0.48%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, ANRO is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check BNTX's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, MRNA has a market cap of 21.4B. Regarding current trading prices, ANRO is priced at $25.47, while MRNA trades at $54.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas MRNA's P/E ratio is -7.47. In terms of profitability, ANRO's ROE is -0.48%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, ANRO is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check MRNA's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, ROIV has a market cap of 21B. Regarding current trading prices, ANRO is priced at $25.47, while ROIV trades at $29.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas ROIV's P/E ratio is -25.12. In terms of profitability, ANRO's ROE is -0.48%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, ANRO is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check ROIV's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, RPRX has a market cap of 20.9B. Regarding current trading prices, ANRO is priced at $25.47, while RPRX trades at $48.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas RPRX's P/E ratio is 27.36. In terms of profitability, ANRO's ROE is -0.48%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, ANRO is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check RPRX's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ANRO is priced at $25.47, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ANRO's ROE is -0.48%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, ANRO is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check BGNE's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, INCY has a market cap of 19.3B. Regarding current trading prices, ANRO is priced at $25.47, while INCY trades at $97.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas INCY's P/E ratio is 15.15. In terms of profitability, ANRO's ROE is -0.48%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ANRO is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check INCY's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ANRO is priced at $25.47, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ANRO's ROE is -0.48%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, ANRO is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ANRO.Check DNA-WT's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, GMAB has a market cap of 18.1B. Regarding current trading prices, ANRO is priced at $25.47, while GMAB trades at $29.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas GMAB's P/E ratio is 19.03. In terms of profitability, ANRO's ROE is -0.48%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, ANRO is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check GMAB's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, SMMT has a market cap of 15.7B. Regarding current trading prices, ANRO is priced at $25.47, while SMMT trades at $21.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas SMMT's P/E ratio is -14.67. In terms of profitability, ANRO's ROE is -0.48%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, ANRO is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for ANRO.Check SMMT's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, BBIO has a market cap of 15.1B. Regarding current trading prices, ANRO is priced at $25.47, while BBIO trades at $77.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas BBIO's P/E ratio is -20.56. In terms of profitability, ANRO's ROE is -0.48%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, ANRO is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check BBIO's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, ASND has a market cap of 14.8B. Regarding current trading prices, ANRO is priced at $25.47, while ASND trades at $241.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas ASND's P/E ratio is -54.93. In terms of profitability, ANRO's ROE is -0.48%, compared to ASND's ROE of +1.28%. Regarding short-term risk, ANRO is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check ASND's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, IONS has a market cap of 12.7B. Regarding current trading prices, ANRO is priced at $25.47, while IONS trades at $76.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas IONS's P/E ratio is -32.28. In terms of profitability, ANRO's ROE is -0.48%, compared to IONS's ROE of -0.69%. Regarding short-term risk, ANRO is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check IONS's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ANRO is priced at $25.47, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ANRO's ROE is -0.48%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ANRO is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check KRTX's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, JAZZ has a market cap of 12.3B. Regarding current trading prices, ANRO is priced at $25.47, while JAZZ trades at $199.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas JAZZ's P/E ratio is -34.13. In terms of profitability, ANRO's ROE is -0.48%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, ANRO is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check JAZZ's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, MDGL has a market cap of 11.9B. Regarding current trading prices, ANRO is priced at $25.47, while MDGL trades at $518.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas MDGL's P/E ratio is -40.36. In terms of profitability, ANRO's ROE is -0.48%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, ANRO is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check MDGL's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, EXEL has a market cap of 11.9B. Regarding current trading prices, ANRO is priced at $25.47, while EXEL trades at $44.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas EXEL's P/E ratio is 15.93. In terms of profitability, ANRO's ROE is -0.48%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, ANRO is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for ANRO.Check EXEL's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ANRO is priced at $25.47, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ANRO's ROE is -0.48%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ANRO is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check RNAM's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, BMRN has a market cap of 10.6B. Regarding current trading prices, ANRO is priced at $25.47, while BMRN trades at $55.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas BMRN's P/E ratio is 30.71. In terms of profitability, ANRO's ROE is -0.48%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, ANRO is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check BMRN's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, ARWR has a market cap of 9.9B. Regarding current trading prices, ANRO is priced at $25.47, while ARWR trades at $70.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas ARWR's P/E ratio is 44.34. In terms of profitability, ANRO's ROE is -0.48%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, ANRO is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for ANRO.Check ARWR's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ANRO is priced at $25.47, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ANRO's ROE is -0.48%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ANRO is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check RXDX's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, AXSM has a market cap of 9.4B. Regarding current trading prices, ANRO is priced at $25.47, while AXSM trades at $184.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas AXSM's P/E ratio is -49.91. In terms of profitability, ANRO's ROE is -0.48%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, ANRO is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check AXSM's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, TECH has a market cap of 9.2B. Regarding current trading prices, ANRO is priced at $25.47, while TECH trades at $58.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas TECH's P/E ratio is 110.36. In terms of profitability, ANRO's ROE is -0.48%, compared to TECH's ROE of +0.04%. Regarding short-term risk, ANRO is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check TECH's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ANRO is priced at $25.47, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ANRO's ROE is -0.48%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ANRO is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check IMGN's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, PCVX has a market cap of 8.7B. Regarding current trading prices, ANRO is priced at $25.47, while PCVX trades at $60.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas PCVX's P/E ratio is -10.74. In terms of profitability, ANRO's ROE is -0.48%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, ANRO and PCVX have similar daily volatility (4.31).Check PCVX's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ANRO is priced at $25.47, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ANRO's ROE is -0.48%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, ANRO is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check BPMC's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ANRO is priced at $25.47, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas CERE's P/E ratio is -16.47. In terms of profitability, ANRO's ROE is -0.48%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ANRO is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check CERE's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, HALO has a market cap of 8.1B. Regarding current trading prices, ANRO is priced at $25.47, while HALO trades at $68.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas HALO's P/E ratio is 26.58. In terms of profitability, ANRO's ROE is -0.48%, compared to HALO's ROE of +0.93%. Regarding short-term risk, ANRO is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check HALO's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, CYTK has a market cap of 8.1B. Regarding current trading prices, ANRO is priced at $25.47, while CYTK trades at $65.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas CYTK's P/E ratio is -10.00. In terms of profitability, ANRO's ROE is -0.48%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, ANRO is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check CYTK's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, IBRX has a market cap of 8B. Regarding current trading prices, ANRO is priced at $25.47, while IBRX trades at $7.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas IBRX's P/E ratio is -20.47. In terms of profitability, ANRO's ROE is -0.48%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, ANRO is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for ANRO.Check IBRX's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, ABVX has a market cap of 8B. Regarding current trading prices, ANRO is priced at $25.47, while ABVX trades at $121.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas ABVX's P/E ratio is -21.55. In terms of profitability, ANRO's ROE is -0.48%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, ANRO is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for ANRO.Check ABVX's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, KRYS has a market cap of 7.9B. Regarding current trading prices, ANRO is priced at $25.47, while KRYS trades at $268.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas KRYS's P/E ratio is 39.26. In terms of profitability, ANRO's ROE is -0.48%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ANRO is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check KRYS's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, NUVL has a market cap of 7.7B. Regarding current trading prices, ANRO is priced at $25.47, while NUVL trades at $104.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas NUVL's P/E ratio is -17.91. In terms of profitability, ANRO's ROE is -0.48%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, ANRO is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check NUVL's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ANRO is priced at $25.47, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ANRO's ROE is -0.48%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, ANRO is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check MTSR's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, KYMR has a market cap of 7.3B. Regarding current trading prices, ANRO is priced at $25.47, while KYMR trades at $89.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas KYMR's P/E ratio is -24.12. In terms of profitability, ANRO's ROE is -0.48%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, ANRO is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check KYMR's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, PRAX has a market cap of 7.2B. Regarding current trading prices, ANRO is priced at $25.47, while PRAX trades at $339.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas PRAX's P/E ratio is -25.22. In terms of profitability, ANRO's ROE is -0.48%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, ANRO is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for ANRO.Check PRAX's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ANRO is priced at $25.47, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ANRO's ROE is -0.48%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, ANRO is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check MRUS's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, BLTE has a market cap of 6.7B. Regarding current trading prices, ANRO is priced at $25.47, while BLTE trades at $168.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas BLTE's P/E ratio is -73.06. In terms of profitability, ANRO's ROE is -0.48%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, ANRO is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check BLTE's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, PTGX has a market cap of 6.7B. Regarding current trading prices, ANRO is priced at $25.47, while PTGX trades at $105.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas PTGX's P/E ratio is -51.43. In terms of profitability, ANRO's ROE is -0.48%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, ANRO is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check PTGX's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ANRO is priced at $25.47, while ACLX trades at $115.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas ACLX's P/E ratio is -28.25. In terms of profitability, ANRO's ROE is -0.48%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ANRO is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check ACLX's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ANRO is priced at $25.47, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas RETA's P/E ratio is -66.29. In terms of profitability, ANRO's ROE is -0.48%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ANRO is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check RETA's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, ANRO is priced at $25.47, while PTCT trades at $73.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas PTCT's P/E ratio is 8.57. In terms of profitability, ANRO's ROE is -0.48%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, ANRO is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check PTCT's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, RYTM has a market cap of 6B. Regarding current trading prices, ANRO is priced at $25.47, while RYTM trades at $87.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas RYTM's P/E ratio is -28.23. In terms of profitability, ANRO's ROE is -0.48%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, ANRO is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for ANRO.Check RYTM's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, CELC has a market cap of 6B. Regarding current trading prices, ANRO is priced at $25.47, while CELC trades at $123.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas CELC's P/E ratio is -32.49. In terms of profitability, ANRO's ROE is -0.48%, compared to CELC's ROE of -2.03%. Regarding short-term risk, ANRO is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for ANRO.Check CELC's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, CAI has a market cap of 5.9B. Regarding current trading prices, ANRO is priced at $25.47, while CAI trades at $20.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas CAI's P/E ratio is -6.51. In terms of profitability, ANRO's ROE is -0.48%, compared to CAI's ROE of +0.25%. Regarding short-term risk, ANRO is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check CAI's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, CNTA has a market cap of 5.9B. Regarding current trading prices, ANRO is priced at $25.47, while CNTA trades at $39.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas CNTA's P/E ratio is -27.13. In terms of profitability, ANRO's ROE is -0.48%, compared to CNTA's ROE of -0.51%. Regarding short-term risk, ANRO is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check CNTA's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, ANRO is priced at $25.47, while COGT trades at $36.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas COGT's P/E ratio is -16.81. In terms of profitability, ANRO's ROE is -0.48%, compared to COGT's ROE of -1.00%. Regarding short-term risk, ANRO is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check COGT's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, CGON has a market cap of 5.7B. Regarding current trading prices, ANRO is priced at $25.47, while CGON trades at $67.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas CGON's P/E ratio is -32.54. In terms of profitability, ANRO's ROE is -0.48%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ANRO is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check CGON's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, ANRO is priced at $25.47, while SRRK trades at $49.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas SRRK's P/E ratio is -14.99. In terms of profitability, ANRO's ROE is -0.48%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, ANRO is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check SRRK's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, ERAS has a market cap of 5.7B. Regarding current trading prices, ANRO is priced at $25.47, while ERAS trades at $18.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas ERAS's P/E ratio is -41.36. In terms of profitability, ANRO's ROE is -0.48%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, ANRO is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for ANRO.Check ERAS's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ANRO is priced at $25.47, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ANRO's ROE is -0.48%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, ANRO is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check CDTX's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, IMVT has a market cap of 5.6B. Regarding current trading prices, ANRO is priced at $25.47, while IMVT trades at $27.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas IMVT's P/E ratio is -10.27. In terms of profitability, ANRO's ROE is -0.48%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, ANRO is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check IMVT's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, ALKS has a market cap of 5.5B. Regarding current trading prices, ANRO is priced at $25.47, while ALKS trades at $33.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas ALKS's P/E ratio is 23.22. In terms of profitability, ANRO's ROE is -0.48%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, ANRO is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check ALKS's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, TGTX has a market cap of 5.5B. Regarding current trading prices, ANRO is priced at $25.47, while TGTX trades at $34.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas TGTX's P/E ratio is 12.49. In terms of profitability, ANRO's ROE is -0.48%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, ANRO is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check TGTX's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ANRO is priced at $25.47, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ANRO's ROE is -0.48%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ANRO is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check ABCM's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ANRO is priced at $25.47, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ANRO's ROE is -0.48%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ANRO is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check ISEE's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, CRSP has a market cap of 5.4B. Regarding current trading prices, ANRO is priced at $25.47, while CRSP trades at $56.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas CRSP's P/E ratio is -8.77. In terms of profitability, ANRO's ROE is -0.48%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, ANRO is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for ANRO.Check CRSP's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, FBIOX has a market cap of 5.4B. Regarding current trading prices, ANRO is priced at $25.47, while FBIOX trades at $25.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas FBIOX's P/E ratio is N/A. In terms of profitability, ANRO's ROE is -0.48%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, ANRO is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check FBIOX's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, APLS has a market cap of 5.2B. Regarding current trading prices, ANRO is priced at $25.47, while APLS trades at $40.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas APLS's P/E ratio is 226.92. In terms of profitability, ANRO's ROE is -0.48%, compared to APLS's ROE of +0.08%. Regarding short-term risk, ANRO is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check APLS's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, APGE has a market cap of 5B. Regarding current trading prices, ANRO is priced at $25.47, while APGE trades at $89.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas APGE's P/E ratio is -21.17. In terms of profitability, ANRO's ROE is -0.48%, compared to APGE's ROE of -0.37%. Regarding short-term risk, ANRO is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check APGE's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, MIRM has a market cap of 4.8B. Regarding current trading prices, ANRO is priced at $25.47, while MIRM trades at $96.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas MIRM's P/E ratio is -205.11. In terms of profitability, ANRO's ROE is -0.48%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, ANRO is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check MIRM's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, TERN has a market cap of 4.7B. Regarding current trading prices, ANRO is priced at $25.47, while TERN trades at $52.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas TERN's P/E ratio is -51.17. In terms of profitability, ANRO's ROE is -0.48%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ANRO is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check TERN's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, CORT has a market cap of 4.7B. Regarding current trading prices, ANRO is priced at $25.47, while CORT trades at $43.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas CORT's P/E ratio is 53.54. In terms of profitability, ANRO's ROE is -0.48%, compared to CORT's ROE of +0.15%. Regarding short-term risk, ANRO is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check CORT's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, XENE has a market cap of 4.6B. Regarding current trading prices, ANRO is priced at $25.47, while XENE trades at $58.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas XENE's P/E ratio is -13.50. In terms of profitability, ANRO's ROE is -0.48%, compared to XENE's ROE of -0.56%. Regarding short-term risk, ANRO is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check XENE's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ANRO is priced at $25.47, while FOLD trades at $14.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas FOLD's P/E ratio is -160.67. In terms of profitability, ANRO's ROE is -0.48%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ANRO is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check FOLD's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ANRO is priced at $25.47, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ANRO's ROE is -0.48%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, ANRO is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check AKRO's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, LGND has a market cap of 4.5B. Regarding current trading prices, ANRO is priced at $25.47, while LGND trades at $225.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas LGND's P/E ratio is 36.72. In terms of profitability, ANRO's ROE is -0.48%, compared to LGND's ROE of +0.14%. Regarding short-term risk, ANRO is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check LGND's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ANRO is priced at $25.47, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ANRO's ROE is -0.48%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ANRO is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check ALPN's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ANRO is priced at $25.47, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas OPT's P/E ratio is -1.52. In terms of profitability, ANRO's ROE is -0.48%, compared to OPT's ROE of +0.88%. Regarding short-term risk, ANRO is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check OPT's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, SYRE has a market cap of 4.2B. Regarding current trading prices, ANRO is priced at $25.47, while SYRE trades at $68.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas SYRE's P/E ratio is -34.84. In terms of profitability, ANRO's ROE is -0.48%, compared to SYRE's ROE of -0.29%. Regarding short-term risk, ANRO is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for ANRO.Check SYRE's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, CRNX has a market cap of 4.2B. Regarding current trading prices, ANRO is priced at $25.47, while CRNX trades at $39.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas CRNX's P/E ratio is -8.03. In terms of profitability, ANRO's ROE is -0.48%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, ANRO is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check CRNX's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ANRO is priced at $25.47, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ANRO's ROE is -0.48%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ANRO is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check MRTX's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, VKTX has a market cap of 4.1B. Regarding current trading prices, ANRO is priced at $25.47, while VKTX trades at $35.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas VKTX's P/E ratio is -11.11. In terms of profitability, ANRO's ROE is -0.48%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, ANRO is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for ANRO.Check VKTX's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, NAMS has a market cap of 3.9B. Regarding current trading prices, ANRO is priced at $25.47, while NAMS trades at $34.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas NAMS's P/E ratio is -19.77. In terms of profitability, ANRO's ROE is -0.48%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, ANRO is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for ANRO.Check NAMS's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, LEGN has a market cap of 3.8B. Regarding current trading prices, ANRO is priced at $25.47, while LEGN trades at $20.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas LEGN's P/E ratio is -12.67. In terms of profitability, ANRO's ROE is -0.48%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, ANRO is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for ANRO.Check LEGN's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, TVTX has a market cap of 3.8B. Regarding current trading prices, ANRO is priced at $25.47, while TVTX trades at $40.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas TVTX's P/E ratio is -71.84. In terms of profitability, ANRO's ROE is -0.48%, compared to TVTX's ROE of -0.79%. Regarding short-term risk, ANRO is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for ANRO.Check TVTX's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ANRO is priced at $25.47, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ANRO's ROE is -0.48%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ANRO is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check RYZB's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ANRO is priced at $25.47, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ANRO's ROE is -0.48%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ANRO is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check CBAY's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, ANRO is priced at $25.47, while ACAD trades at $21.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas ACAD's P/E ratio is 9.46. In terms of profitability, ANRO's ROE is -0.48%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, ANRO is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check ACAD's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, DNTH has a market cap of 3.7B. Regarding current trading prices, ANRO is priced at $25.47, while DNTH trades at $95.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas DNTH's P/E ratio is -22.80. In terms of profitability, ANRO's ROE is -0.48%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, ANRO is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check DNTH's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, EWTX has a market cap of 3.6B. Regarding current trading prices, ANRO is priced at $25.47, while EWTX trades at $33.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas EWTX's P/E ratio is -20.67. In terms of profitability, ANRO's ROE is -0.48%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, ANRO is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check EWTX's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, TLX has a market cap of 3.6B. Regarding current trading prices, ANRO is priced at $25.47, while TLX trades at $10.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas TLX's P/E ratio is -533.00. In terms of profitability, ANRO's ROE is -0.48%, compared to TLX's ROE of -0.02%. Regarding short-term risk, ANRO is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check TLX's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ANRO is priced at $25.47, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ANRO's ROE is -0.48%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, ANRO is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check SWTX's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, LQDA has a market cap of 3.5B. Regarding current trading prices, ANRO is priced at $25.47, while LQDA trades at $40.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas LQDA's P/E ratio is -50.15. In terms of profitability, ANRO's ROE is -0.48%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, ANRO is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check LQDA's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, DNLI has a market cap of 3.4B. Regarding current trading prices, ANRO is priced at $25.47, while DNLI trades at $21.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas DNLI's P/E ratio is -7.30. In terms of profitability, ANRO's ROE is -0.48%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, ANRO is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for ANRO.Check DNLI's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, KNSA has a market cap of 3.4B. Regarding current trading prices, ANRO is priced at $25.47, while KNSA trades at $45.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas KNSA's P/E ratio is 61.19. In terms of profitability, ANRO's ROE is -0.48%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, ANRO is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for ANRO.Check KNSA's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, DYN has a market cap of 3.3B. Regarding current trading prices, ANRO is priced at $25.47, while DYN trades at $19.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas DYN's P/E ratio is -5.76. In terms of profitability, ANRO's ROE is -0.48%, compared to DYN's ROE of -0.61%. Regarding short-term risk, ANRO is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for ANRO.Check DYN's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, CPRX has a market cap of 3.2B. Regarding current trading prices, ANRO is priced at $25.47, while CPRX trades at $25.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas CPRX's P/E ratio is 15.39. In terms of profitability, ANRO's ROE is -0.48%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ANRO is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ANRO.Check CPRX's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, BEAM has a market cap of 3.1B. Regarding current trading prices, ANRO is priced at $25.47, while BEAM trades at $30.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas BEAM's P/E ratio is -37.88. In terms of profitability, ANRO's ROE is -0.48%, compared to BEAM's ROE of -0.07%. Regarding short-term risk, ANRO is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for ANRO.Check BEAM's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, GPCR has a market cap of 3.1B. Regarding current trading prices, ANRO is priced at $25.47, while GPCR trades at $54.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas GPCR's P/E ratio is -22.60. In terms of profitability, ANRO's ROE is -0.48%, compared to GPCR's ROE of -0.15%. Regarding short-term risk, ANRO is less volatile compared to GPCR. This indicates potentially lower risk in terms of short-term price fluctuations for ANRO.Check GPCR's competition here

ANRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANRO stands at 811.1M. In comparison, VERA has a market cap of 3.1B. Regarding current trading prices, ANRO is priced at $25.47, while VERA trades at $43.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANRO currently has a P/E ratio of -11.59, whereas VERA's P/E ratio is -9.32. In terms of profitability, ANRO's ROE is -0.48%, compared to VERA's ROE of -0.60%. Regarding short-term risk, ANRO is less volatile compared to VERA. This indicates potentially lower risk in terms of short-term price fluctuations for ANRO.Check VERA's competition here